These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10070992)

  • 21. Pressor responses to antihypertensive drug types.
    Alderman MH; Cohen HW; Sealey JE; Laragh JH
    Am J Hypertens; 2010 Sep; 23(9):1031-7. PubMed ID: 20725055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologic tailoring of therapy for resistant hypertension: 20 years' experience with stimulated renin profiling.
    Spence JD
    Am J Hypertens; 1999 Nov; 12(11 Pt 1):1077-83. PubMed ID: 10604483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aliskiren for hypertension: just another option or something truly unique?
    Lee S
    S D Med; 2007 Oct; 60(10):405-6. PubMed ID: 18019776
    [No Abstract]   [Full Text] [Related]  

  • 24. [Long-term drug therapy of arterial hypertension including patient compliance].
    Linss G; Kiesewetter R
    Z Arztl Fortbild (Jena); 1984; 78(24):1047-53. PubMed ID: 6442069
    [No Abstract]   [Full Text] [Related]  

  • 25. Renin and age as determinants of a predominantly betablocker-based antihypertensive drug program.
    Bühler FR; Lütold BE
    Adv Nephrol Necker Hosp; 1976; 6():303-17. PubMed ID: 14485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the renin-angiotensin system in hypertension in the elderly.
    Nagano M; Higaki J; Mikami H; Ogihara T
    Blood Press Suppl; 1994; 5():130-3. PubMed ID: 7889195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antihypertensive effects of coenzyme Q10 in essential hypertension--in relation to the renin-aldosterone system].
    Hata S; Kunida H; Oyama Y
    Horumon To Rinsho; 1977 Sep; 25(9):1019-23. PubMed ID: 923110
    [No Abstract]   [Full Text] [Related]  

  • 28. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension.
    Collart F; Staroukine M; Verniory A
    Acta Cardiol; 1985; 40(3):269-76. PubMed ID: 3895792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic implications of plasma renin in essential hypertension.
    Kaplan NM
    JAMA; 1975 Jan; 231(2):167-70. PubMed ID: 1172683
    [No Abstract]   [Full Text] [Related]  

  • 30. [Monitoring of arterial blood pressure in the evaluation of antihypertensive treatment].
    Pessina AC; Palatini P; Dal Palù C
    G Ital Cardiol; 1988 Oct; 18(10):890-4. PubMed ID: 3246325
    [No Abstract]   [Full Text] [Related]  

  • 31. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
    Gradman AH; Traub D
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma renin testing to guide antihypertensive therapy.
    Viera AJ; Furberg CD
    Curr Hypertens Rep; 2015 Jan; 17(1):506. PubMed ID: 25432898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
    Stanton A; Jensen C; Nussberger J; O'Brien E
    Hypertension; 2003 Dec; 42(6):1137-43. PubMed ID: 14597641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.
    van den Meiracker AH; Admiraal PJ; Man in 't Veld AJ; Derkx FH; Ritsema van Eck HJ; Mulder P; van Brummelen P; Schalekamp MA
    BMJ; 1990 Jul; 301(6745):205-10. PubMed ID: 2203486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension.
    Shah S; Coakley C; Hough A; Parra D
    Ann Pharmacother; 2013 Nov; 47(11):1562-8. PubMed ID: 24285769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of angiotensin II receptors antagonist losartan on metabolism and morphofunctional condition myocardium in hypertensive patients].
    Didenko VA; Simonov DV
    Klin Med (Mosk); 1998; 76(9):33-7. PubMed ID: 9821371
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hypertension and renin/angiotensin. Physiopathological and therapeutical aspects].
    Jorgensen H
    Tidsskr Nor Laegeforen; 1975 Dec; 95(34-36):1988-91. PubMed ID: 1209575
    [No Abstract]   [Full Text] [Related]  

  • 39. [Antihypertensive therapy in young hypertensive patients. Effect of tredalat in comparison with adalat on blood pressure behavior and metabolism, especially renin excretion].
    Klimm HD; Voigt ED
    Fortschr Med; 1988 Feb; 106(6):118-22. PubMed ID: 3286427
    [No Abstract]   [Full Text] [Related]  

  • 40. Changes in blood pressure, plasma catecholamines and plasma renin activity during and after treatment with tiamenidine and clonidine.
    Hansson BG; Hökfelt B
    Br J Clin Pharmacol; 1981 Jan; 11(1):73-7. PubMed ID: 7011348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.